EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement

Rupa Ahluwalia iD, Stephanie E Baldeweg, Kristien Boelaert, Krishna Chatterjee iD, Colin Dayan, Onyebuchi Okosieme iD, Julia Priestley, Peter Taylor iD, Bijay Vaidya iD, Nicola Zammitt, Simon H Pearce iD

Clinical Endocrinology · 2023-08 · 99 (2) · 206-216

DOI: 10.1111/cen.14935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, online erschienen am 05.06.2023. Verfasst von Rupa Ahluwalia und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes & Endocrinology, Norfolk and Norwich University Hospitals NHS Trust, Norwich, UK. Hauptthemen laut MEDLINE: Triiodothyronine, Hypothyroidism. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Persistent symptoms in patients treated for hypothyroidism are common. Despite more than 20 years of debate, the use of liothyronine for this indication remains controversial, as numerous randomised trials have failed to show a benefit of treatment regimens that combine liothyronine (T3) with levothyroxine over levothyroxine monotherapy. This consensus statement attempts to provide practical guidance to clinicians faced with patients who have persistent symptoms during thyroid hormone replacement therapy. It applies to non‐pregnant adults and is focussed on care delivered within the UK National Health Service, although it may be relevant in other healthcare environments. The statement emphasises several key clinical practice points for patients dissatisfied with treatment for hypothyroidism. Firstly, it is important to establish a diagnosis of overt hypothyroidism; patients with persistent symptoms during thyroid hormone replacement but with no clear biochemical evidence of overt hypothyroidism should first have a trial without thyroid hormone replacement. In those with established overt hypothyroidism, levothyroxine doses should be optimised aiming for a TSH in the 0.3–2.0 mU/L range for 3 to 6 months before a therapeutic response can be assessed. In some patients, it may be acceptable to have serum TSH below reference range (e.g. 0.1–0.3 mU/L), but not fully suppressed in the long term. We suggest that for some patients with confirmed overt hypothyroidism and persistent symptoms who have had adequate treatment with levothyroxine and in whom other comorbidities have been excluded, a trial of liothyronine/levothyroxine combined therapy may be warranted. The decision to start treatment with liothyronine should be a shared decision between patient and clinician. However, individual clinicians should not feel obliged to start liothyronine or to continue liothyronine medication provided by other health care practitioners or accessed without medical advice, if they judge this not to be in the patient's best interest.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriiodothyronineHypothyroidismAdultHumansThyroxineState MedicineThyrotropin

Stichwörter der Autor:innen

hypothyroidismlevothyroxineliothyroninesubclinical hypothyroidismtri-iodothyronine

Substanzen

TriiodothyronineThyroxineThyrotropin

Autor:innen und Institutionen

  • Department of Diabetes & Endocrinology, Norfolk and Norwich University Hospitals NHS Trust, Norwich, UK.
  • Department of Diabetes & Endocrinology, University College London, London, UK.
  • Centre for Obesity & Metabolism, Department of Experimental & Translational Medicine, Division of Medicine, University College London Hospitals, London, UK.
  • The RCP Joint Specialties Committee and The Clinical Committee, Society for Endocrinology, Bristol, UK.
  • Institute for Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • Wellcome-MRC Institute of Metabolic Sciences, University of Cambridge, Cambridge, UK.

ORCID-Profile: Rupa Ahluwalia, Krishna Chatterjee, Onyebuchi Okosieme, Peter Taylor, Bijay Vaidya, Simon H Pearce

Förderung

  • Medical Research Council

Zitieren

APA

Ahluwalia, R., Baldeweg, S. E., Boelaert, K., Chatterjee, K., Dayan, C., Okosieme, O., Priestley, J., Taylor, P., Vaidya, B., Zammitt, N., & Pearce, S. H. (2023). Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement. Clinical Endocrinology, 99(2), 206-216. https://doi.org/10.1111/cen.14935

Vancouver

Ahluwalia R, Baldeweg SE, Boelaert K, Chatterjee K, Dayan C, Okosieme O, et al. Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement. Clinical Endocrinology. 2023;99(2):206-216. doi:10.1111/cen.14935

BibTeX
@article{Ahluwalia2023,
  author = {Ahluwalia, Rupa and Baldeweg, Stephanie E and Boelaert, Kristien and Chatterjee, Krishna and Dayan, Colin and Okosieme, Onyebuchi and Priestley, Julia and Taylor, Peter and Vaidya, Bijay and Zammitt, Nicola and Pearce, Simon H},
  title = {Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement},
  journal = {Clinical Endocrinology},
  year = {2023},
  volume = {99},
  number = {2},
  pages = {206--216},
  doi = {10.1111/cen.14935}
}
Kostenlos starten →